Cervical Cancer - Pipeline Review, H2 2017

Publisher Name :
Date: 30-Nov-2017
No. of pages: 674
Inquire Before Buying

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer - Pipeline Review, H2 2017, provides an overview of the Cervical Cancer (Oncology) pipeline landscape.

Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge and low back pain.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cervical Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 34, 36, 47, 9 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 4, 11 and 6 molecules, respectively.

Cervical Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Cancer (Oncology).

  • The pipeline guide reviews pipeline therapeutics for Cervical Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Cervical Cancer (Oncology) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Cervical Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Cancer (Oncology)


Reasons to buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Cervical Cancer (Oncology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Cervical Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Cervical Cancer - Pipeline Review, H2 2017

Table of Contents

Table of Contents 2
Introduction 7
Cervical Cancer - Overview 8
Cervical Cancer - Therapeutics Development 9
Cervical Cancer - Therapeutics Assessment 30
Cervical Cancer - Companies Involved in Therapeutics Development 44
Cervical Cancer - Drug Profiles 85
Cervical Cancer - Dormant Projects 640
Cervical Cancer - Discontinued Products 645
Cervical Cancer - Product Development Milestones 646
Appendix 657

List of Tables

Number of Products under Development for Cervical Cancer, H2 2017 25
Number of Products under Development by Companies, H2 2017 27
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 28
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 29
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 30
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 31
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 32
Number of Products under Development by Universities/Institutes, H2 2017 33
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 35
Products under Development by Companies, H2 2017 36
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 37
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 38
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 39
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 40
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 41
Products under Development by Companies, H2 2017 (Contd..6), H2 2017 42
Products under Development by Companies, H2 2017 (Contd..7), H2 2017 43
Products under Development by Universities/Institutes, H2 2017 44
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 45
Number of Products by Stage and Target, H2 2017 47
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 48
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 49
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 50
Number of Products by Stage and Mechanism of Action, H2 2017 52
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 53
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 54
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 55
Number of Products by Stage and Route of Administration, H2 2017 57
Number of Products by Stage and Molecule Type, H2 2017 59
Cervical Cancer - Pipeline by Abion Inc, H2 2017 60
Cervical Cancer - Pipeline by Abivax SA, H2 2017 60
Cervical Cancer - Pipeline by Admedus Ltd, H2 2017 61
Cervical Cancer - Pipeline by Advaxis Inc, H2 2017 61
Cervical Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017 62
Cervical Cancer - Pipeline by Agenus Inc, H2 2017 62
Cervical Cancer - Pipeline by Amgen Inc, H2 2017 63
Cervical Cancer - Pipeline by AntiCancer Inc, H2 2017 63
Cervical Cancer - Pipeline by Antigen Express Inc, H2 2017 63
Cervical Cancer - Pipeline by Arbor Vita Corp, H2 2017 64
Cervical Cancer - Pipeline by ArQule Inc, H2 2017 64
Cervical Cancer - Pipeline by Asana BioSciences LLC, H2 2017 65
Cervical Cancer - Pipeline by AstraZeneca Plc, H2 2017 65
Cervical Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017 66
Cervical Cancer - Pipeline by Bayer AG, H2 2017 66
Cervical Cancer - Pipeline by BeiGene Ltd, H2 2017 67
Cervical Cancer - Pipeline by Bioleaders Corp, H2 2017 67
Cervical Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H2 2017 67
Cervical Cancer - Pipeline by Blirt SA, H2 2017 68
Cervical Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017 68
Cervical Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017 69
Cervical Cancer - Pipeline by Cadila Healthcare Ltd, H2 2017 69
Cervical Cancer - Pipeline by Cancer Research Technology Ltd, H2 2017 69
Cervical Cancer - Pipeline by Celleron Therapeutics Ltd, H2 2017 70
Cervical Cancer - Pipeline by Coherus BioSciences Inc, H2 2017 70
Cervical Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2017 71
Cervical Cancer - Pipeline by Cytori Therapeutics Inc, H2 2017 71
Cervical Cancer - Pipeline by CZ BioMed Corp, H2 2017 72
Cervical Cancer - Pipeline by DelMar Pharmaceuticals Inc, H2 2017 72
Cervical Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2017 73
Cervical Cancer - Pipeline by Eisai Co Ltd, H2 2017 73
Cervical Cancer - Pipeline by Etubics Corp, H2 2017 73
Cervical Cancer - Pipeline by Eureka Therapeutics Inc, H2 2017 74
Cervical Cancer - Pipeline by EyeGene Inc, H2 2017 74
Cervical Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 75
Cervical Cancer - Pipeline by Formune SL, H2 2017 75
Cervical Cancer - Pipeline by GamaMabs Pharma SA, H2 2017 76
Cervical Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2017 76
Cervical Cancer - Pipeline by Genentech Inc, H2 2017 77
Cervical Cancer - Pipeline by Genmab A/S, H2 2017 77
Cervical Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2017 77
Cervical Cancer - Pipeline by GlaxoSmithKline Plc, H2 2017 78
Cervical Cancer - Pipeline by Glycostem Therapeutics BV, H2 2017 78
Cervical Cancer - Pipeline by Glycotope GmbH, H2 2017 79
Cervical Cancer - Pipeline by Gradalis Inc, H2 2017 79
Cervical Cancer - Pipeline by Immunomedics Inc, H2 2017 80
Cervical Cancer - Pipeline by Immunovaccine Inc, H2 2017 80
Cervical Cancer - Pipeline by Innate Pharma SA, H2 2017 81
Cervical Cancer - Pipeline by Innovation Pharmaceuticals Inc, H2 2017 81
Cervical Cancer - Pipeline by Iovance Biotherapeutics Inc, H2 2017 81
Cervical Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2017 82
Cervical Cancer - Pipeline by Johnson & Johnson, H2 2017 82
Cervical Cancer - Pipeline by Juno Therapeutics Inc, H2 2017 83
Cervical Cancer - Pipeline by Kaketsuken, H2 2017 83
Cervical Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2017 84
Cervical Cancer - Pipeline by Kite Pharma Inc, H2 2017 84
Cervical Cancer - Pipeline by LondonPharma Ltd, H2 2017 85
Cervical Cancer - Pipeline by Mabion SA, H2 2017 85
Cervical Cancer - Pipeline by MedImmune LLC, H2 2017 86
Cervical Cancer - Pipeline by Merck & Co Inc, H2 2017 86
Cervical Cancer - Pipeline by Merck KGaA, H2 2017 87
Cervical Cancer - Pipeline by Mycenax Biotech Inc, H2 2017 87
Cervical Cancer - Pipeline by Nektar Therapeutics, H2 2017 88
Cervical Cancer - Pipeline by NeoImmuneTech Inc, H2 2017 88
Cervical Cancer - Pipeline by Ology Bioservices Inc, H2 2017 88
Cervical Cancer - Pipeline by Oncobiologics Inc, H2 2017 89
Cervical Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 90
Cervical Cancer - Pipeline by Oryx GmbH & Co KG, H2 2017 90
Cervical Cancer - Pipeline by PDS Biotechnology Corp, H2 2017 90
Cervical Cancer - Pipeline by Pfizer Inc, H2 2017 91
Cervical Cancer - Pipeline by Pharma Mar SA, H2 2017 91
Cervical Cancer - Pipeline by Psicofarma SA de CV, H2 2017 92
Cervical Cancer - Pipeline by Puma Biotechnology Inc, H2 2017 92
Cervical Cancer - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 93
Cervical Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H2 2017 93
Cervical Cancer - Pipeline by Richter Gedeon Nyrt, H2 2017 94
Cervical Cancer - Pipeline by Samyang Holdings Corp, H2 2017 94
Cervical Cancer - Pipeline by Sanofi, H2 2017 95
Cervical Cancer - Pipeline by Seattle Genetics Inc, H2 2017 95
Cervical Cancer - Pipeline by Selecta Biosciences Inc, H2 2017 96
Cervical Cancer - Pipeline by Shantha Biotechnics Pvt Ltd, H2 2017 96
Cervical Cancer - Pipeline by Sirnaomics Inc, H2 2017 96
Cervical Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 97
Cervical Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2017 97
Cervical Cancer - Pipeline by Theralase Technologies Inc, H2 2017 98
Cervical Cancer - Pipeline by Theravectys SA, H2 2017 98
Cervical Cancer - Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2017 98
Cervical Cancer - Pipeline by UbiVac LLC, H2 2017 99
Cervical Cancer - Pipeline by Vectorite Biomedica Inc, H2 2017 99
Cervical Cancer - Pipeline by VLPbio, H2 2017 99
Cervical Cancer - Pipeline by Wellstat Biologics Corp, H2 2017 100
Cervical Cancer - Pipeline by Zeria Pharmaceutical Co Ltd, H2 2017 100
Cervical Cancer - Dormant Projects, H2 2017 656
Cervical Cancer - Dormant Projects, H2 2017 (Contd..1), H2 2017 657
Cervical Cancer - Dormant Projects, H2 2017 (Contd..2), H2 2017 658
Cervical Cancer - Dormant Projects, H2 2017 (Contd..3), H2 2017 659
Cervical Cancer - Dormant Projects, H2 2017 (Contd..4), H2 2017 660
Cervical Cancer - Discontinued Products, H2 2017 661

List of Figures

Number of Products under Development for Cervical Cancer, H2 2017 25
Number of Products under Development by Companies, H2 2017 26
Number of Products under Development by Universities/Institutes, H2 2017 33
Number of Products by Top 10 Targets, H2 2017 46
Number of Products by Stage and Top 10 Targets, H2 2017 46
Number of Products by Top 10 Mechanism of Actions, H2 2017 51
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 51
Number of Products by Routes of Administration, H2 2017 56
Number of Products by Stage and Routes of Administration, H2 2017 56
Number of Products by Top 10 Molecule Types, H2 2017 58
Number of Products by Stage and Top 10 Molecule Types, H2 2017 58

  • Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 27-Jun-2018        Price: US 3480 Onwards        Pages: 150
    Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect. Cancer stem cells (CSCs) are cancer cells tha......
  • Pancreatic Cancer - Pipeline Review, H1 2018
    Published: 22-Jun-2018        Price: US 2500 Onwards        Pages: 2509
    Pancreatic Cancer - Pipeline Review, H1 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H1 2018, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may ......
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2018
    Published: 22-Jun-2018        Price: US 2000 Onwards        Pages: 853
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2018, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline landscape. Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss ......
  • Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018
    Published: 22-Jun-2018        Price: US 2500 Onwards        Pages: 1759
    Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape. Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells wit......
  • Global Non-small Cell Lung Cancer Therapeutics Sales Market Report 2018
    Published: 18-Jun-2018        Price: US 4000 Onwards        Pages: 105
    This report studies the global Non-small Cell Lung Cancer Therapeutics market status and forecast, categorizes the global Non-small Cell Lung Cancer Therapeutics market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer othe......
  • Global Non-small Cell Lung Cancer Therapeutics Market Research Report 2018
    Published: 18-Jun-2018        Price: US 2900 Onwards        Pages: 94
    This report studies the global Non-small Cell Lung Cancer Therapeutics market status and forecast, categorizes the global Non-small Cell Lung Cancer Therapeutics market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC ......
  • Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size, Status and Forecast 2025
    Published: 13-Jun-2018        Price: US 3300 Onwards        Pages: 104
    This report studies the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market by companies, region, type and end-use industry. Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumo......
  • 2018-2023 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Report (Status and Outlook)
    Published: 06-Jun-2018        Price: US 4660 Onwards        Pages: 153
    In this report, LP Information studies the present scenario (with the base year being 2017) and the growth prospects of global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market for 2018-2023. Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs ......
  • Global Cancer Gene Therapy Market Professional Survey Report 2018
    Published: 05-Jun-2018        Price: US 3500 Onwards        Pages: 120
    This report studies the global Cancer Gene Therapy market status and forecast, categorizes the global Cancer Gene Therapy market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). The global Cancer Gene Therapy market is valued at xx million US$ in 2017 and is expected to reach xx milli......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs